Otsuka announced positive results of Phase 3 clinical trials of centanafadine for the treatment of adolescents and children with ADHD.
Otsuka Pharmaceutical Companies (U.S.) and its U.S. subsidiary, Otsuka Pharmaceutical Development & Commercialization, Inc. today announced positive results of two, 6-week, Phase 3 clinical trials that evaluated the efficacy, safety, and tolerability of centanafadine for the treatment of adolescents and…